Evidence map›Paper›PMID 28921624›Full record

Trial reportBritish journal of clinical pharmacology2018

Pharmacodynamics and pharmacokinetics of ticagrelor vs. clopidogrel in patients with acute coronary syndromes and chronic kidney disease.

Heyang Wang, Jing Qi, Yi Li, Yunbiao Tang, Chao Li, Jing Li, Yaling Han

Registry-linked trialOpen access · bronzeAbstract readComparative StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in British journal of clinical pharmacology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06216821 (OPT-CAD Score Guided Dual Antiplatelet De-escalation Time in Patients With Acute Coronary Syndrome Undergoing Undergoing Percutaneous Coronary Intervention), which is not on this map. Cited by 22 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed, 1 pooled it
1.6field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06216821 narecruitingnot on this mapstarted 2024, after this paper: background citation

OPT-CAD Score Guided Dual Antiplatelet De-escalation Time in Patients With Acute Coronary Syndrome Undergoing Undergoing Percutaneous Coronary Intervention: a Register-based Randomized Controlled Study

TypeinterventionalSponsorShenyang Northern HospitalRan2024 to 2027Enrolled3,490ConditionsAcute Coronary SyndromeArmsstandard DAPT, OPT-CAD score guided DAPT de-escalation
3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 1 synthesis or guideline pooled it, 35 citations in OpenAlex.

  1. Antiplatelet agents for chronic kidney disease.The Cochrane database of systematic reviews · 2022
    Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Review
  13. Review
  14. Article
  15. Article
  16. Review
  17. Review
  18. Article
  19. Observational
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Heyang WangGeneral Hospital of Shenyang Military Region, Shenyang, China.ORCID http://orcid.org/0000-0001-6651-1901
Jing QiGeneral Hospital of Shenyang Military Region, Shenyang, China.
Yi LiGeneral Hospital of Shenyang Military Region, Shenyang, China.
Yunbiao TangGeneral Hospital of Shenyang Military Region, Shenyang, China.
Chao LiGeneral Hospital of Shenyang Military Region, Shenyang, China.
Jing LiGeneral Hospital of Shenyang Military Region, Shenyang, China.
Yaling HanGeneral Hospital of Shenyang Military Region, Shenyang, China.
General Hospital of Shenyang Military Region · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPivotal clinical trials found that ticagrelor reduced ischaemic complications to a greater extent than clopidogrel, and also that the benefit gradually increased with the reduction in creatinine clearance. However, the underlying mechanisms remains poorly explored.

methodsThis was a single-centre, prospective, randomized clinical trial involving 60 hospitalized Adenosine Diphosphate (ADP) P2Y12 receptor inhibitor-naïve patients with chronic kidney disease (CKD) (estimated glomerular filtration rate <60 ml min

resultsBaseline characteristics were well matched between the two groups. Our results indicated a markedly lower PRU in patients treated with ticagrelor vs. clopidogrel at 30 days (32.6 ± 11.29 vs. 203.7 ± 17.92; P < 0.001) as well as at 2 h, 8 h and 24 h after the loading dose (P < 0.001). Ticagrelor and its active metabolite AR-C124910XX showed a similar time to reach maximum concentration (C

conclusionTicagrelor showed much more potent platelet inhibition in comparison with clopidogrel in patients with CKD and NSTE-ACS.

Indexed as

Acute Coronary SyndromeAdenosineAgedClopidogrelCreatinineFemaleGlomerular Filtration RateHumansKidneyMaleMiddle AgedPlatelet AggregationPlatelet Aggregation InhibitorsPlatelet Function TestsProspective StudiesPurinergic P2Y Receptor AntagonistsAdenosineAR C124910XXClopidogrelCreatininePlatelet Aggregation InhibitorsPurinergic P2Y Receptor AntagonistsTicagrelorTiclopidinechronic kidney diseasenon-ST-elevation acute coronary syndromespharmacodynamicsticagrelor

Identifiers

PMID28921624
PMCPMC5736840
OpenAlexW2755345907

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.